Evaluation of Substance P Neurotransmission in Panic Disorder by PET Imaging of NK1 Receptors With [18F]SPA-RQ

Exclusion Criteria

• •History of psychiatric disease, substance dependence or traumatic brain injury, severe systemic disease, poor vision or hearing
• •History of substance abuse within 6 months
• •Abnormal laboratory tests, including HIV test
• •Any prior participation in other research protocols involving radiation exposure within the past year
• •Prior participation in other research protocols within the past year such that a radiation exposure together with the present study would exceed the annual limits. Limits: A total effective dose 2.5 rem in a year and 2.5 rad per year to the lens of the eyes, gonads and blood-forming organs; and 7.5 rad annually for all other organs.
• •Pregnancy and Breast Feeding.
• •Positive HIV test
• •DSM-IV Axis I diagnostic criteria such as history of, or current Dx ADHD, mood/anxiety disorder, alcohol or psychoactive substance abuse/dependence
• •Psychotropic medication or other drugs that may cross the blood brain barrier
• •Traumatic brain injury, severe systemic disease
• •Abnormal MRI other than minor atrophy
• •Abnormal laboratory tests, including HIV test
• •Claustrophobia
• •Pregnancy or breast feeding
• •Prior participation in other research protocols within the past year such that a radiation exposure together with the present study would exceed the annual limits. Limits: A total effective dose or 5.0 rem in a year
• •Any condition that increases risk for MRI (e.g., pacemaker, metallic foreign body in the eye, etc.)
• •Single radial and ulnar arterial circulation
• •Individuals who recently donated blood
• •Unable to lay on one's back for PET/MRI scans
• •Novocaine allergy
• •Positive HIV test
• •For Patients and Controls:
• •Current diagnosis of substance abuse or dependence
• •History of substance dependence
• •Psychotropic medication in last 3 weeks (8 weeks for fluoxetine/Prozac) except for benzodiazepene during PET or MRI scans
• •Abnormal MRI other than minor atrophy
• •Abnormal laboratory tests, including HIV test
• •Pulmonary disease (e.g. COPD, asthma)
• •Claustrophobia
• •History of hypertension, coronary artery disease and subjects who are taking sympathomimetic medications
• •Pregnancy or breastfeeding
• •Prior participation in other research protocols within the past year such that a radiation exposure together with the present study would exceed the annual limits. Limits: A total effective dose or 5.0 rem in a year
• •Unable to lay on one's back for PET/MRI scans
• •Any condition that increases risk for MRI (e.g., pacemaker, metallic foreign body in the eye, etc.)
• •For Patients and Controls:
• •Current diagnosis of substance abuse or dependence
• •History of substance dependence
• •Psychotropic medication in last 3 weeks (8 weeks for fluoxetine/Prozac) except for benzodiazepene during PET or MRI scans
• •Abnormal MRI other than minor atrophy
• •Abnormal laboratory tests, including HIV test
• •Pulmonary disease (e.g. COPD)
• •Claustrophobia
• •History of hypertension, coronary artery disease and subjects who are taking sympathomimetic medications
• •Pregnancy or breastfeeding
• •Prior participation in other research protocols within the past year such that a radiation exposure together with the present study would exceed the annual limits. Limits: A total effective dose or 5.0 rem in a year
• •Unable to lay on one's back for PET/MRI scans
• •Any condition that increases risk for MRI (e.g., pacemaker, metallic foreign body in the eye, etc.)